This article was originally published in The Gray Sheet
Executive SummarySpinal implant developer raises $9.3 mil. in sale of Series D preferred stock. Proceeds will be used to expand the Austin, Texas firm's sales force, fund ongoing clinical trials of the Infix interbody fusion device, and for R&D projects including gene therapy products for the spine. The privately held firm has raised over $21 mil. since its inception in June 1996
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.